SLIT2 and acute myeloid leukemia: Low expression of SLIT1 was observed in 86.08% of AML group but in 34.78% in the control group (p < 0.0001), and low SLIT2 expression was observed in 96.2% of AML patients and in 73.91% of controls (p = 0.003).